Association of calcium channel blocker use with clinical outcome of COVID-19: A meta-analysis

AIMS: This meta-analysis aims to analyze the association of calcium channel blocker (CCB) use with COVID-19 clinical outcomes. METHODS: PubMed, ProQuest, Science Direct, Scopus, and medRxiv databases were searched systematically in a limited period. The primary outcome was mortality. RESULTS: A tota...

Descripción completa

Detalles Bibliográficos
Autores principales: Alsagaff, Mochamad Yusuf, Mulia, Eka Prasetya Budi, Maghfirah, Irma, Luke, Kevin, Nugraha, David, Rachmi, Dita Aulia, Septianda, Imanita, A'yun, Maya Qurota
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Diabetes India. Published by Elsevier Ltd. 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8282943/
https://www.ncbi.nlm.nih.gov/pubmed/34298269
http://dx.doi.org/10.1016/j.dsx.2021.102210
Descripción
Sumario:AIMS: This meta-analysis aims to analyze the association of calcium channel blocker (CCB) use with COVID-19 clinical outcomes. METHODS: PubMed, ProQuest, Science Direct, Scopus, and medRxiv databases were searched systematically in a limited period. The primary outcome was mortality. RESULTS: A total of 119,298 patients from 31 eligible studies were included. Pooled analysis of the random-effect model revealed CCB was not associated with reduced mortality (OR = 1.21 [95%CI: 0.98–1.49], p = 0.08). Interestingly, subgroup analysis in hypertensive patients revealed significantly reduced mortality (OR = 0.69 [95%CI: 0.52–0.91], p = 0.009). CONCLUSION: CCB usage was not associated with the outcome of COVID-19. However, CCB was associated with a decreased mortality rate in hypertensive COVID-19 patients.

Ejemplares similares